Type 2 diabetes mellitus is characterized by functional and biochemical changes in the central nervous system even under satisfactory glycemic control. Therapy with empagliflozin has a neuroprotective effect, manifested in an improvement in cognitive status and a decrease in NLC level. Empagliflozin reduces neuronal damage and abnormal microglial activation.
Keyphrases
- glycemic control
- cerebral ischemia
- type diabetes
- blood glucose
- resting state
- white matter
- weight loss
- subarachnoid hemorrhage
- functional connectivity
- insulin resistance
- brain injury
- blood brain barrier
- oxidative stress
- cerebrospinal fluid
- lipopolysaccharide induced
- cardiovascular disease
- neuropathic pain
- metabolic syndrome
- multiple sclerosis
- mesenchymal stem cells
- skeletal muscle